Profound Medical Corp. (PRN)
TSX 
Summary
PRN Chart
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Profound Medical Q1 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported by new clinical data, payer progress and a growing installed base.
Profound Medical Corp. (PRN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Profound Medical Corp. ever had a stock split?
Profound Medical Corp. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Arun Swarup Menawat CEO | TSX Exchange | CA74319B5027 ISIN |
| CA Country | 142 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Profound Medical Corp. is a commercial-stage medical device company that focuses on developing magnetic resonance guided ablation procedures. These revolutionary procedures are designed for treating various conditions such as prostate disease, uterine fibroids, and providing palliative pain treatment. The company has a global presence with operations in Canada, Germany, the United States, and Finland. With its headquarters located in Mississauga, Canada, Profound Medical Corp. leverages state-of-the-art technology to improve patient care in hospitals and treatment facilities worldwide.
Products and Services
- TULSA-PRO System: This innovative system works seamlessly with magnetic resonance imaging (MRI) scanners to provide a highly precise treatment option for prostate disease. It is designed to deliver targeted therapy with minimal invasiveness, aiming to reduce side effects and improve recovery times for patients. The TULSA-PRO system underscores Profound Medical Corp.’s commitment to advancing prostate disease treatment through technology.
- Sonalleve: Sonalleve is a versatile therapeutic platform that offers non-invasive treatment solutions for uterine fibroids and palliative pain relief for patients suffering from bone metastases. The technology behind Sonalleve uses high-intensity focused ultrasound (HIFU) to target and treat the affected areas without the need for surgical intervention. This platform demonstrates the company’s dedication to providing innovative and patient-centric treatments for complex health issues.
